Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks joint health in hemophilia a patients on prophylaxis

NCT ID NCT06684314

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study in Taiwan will follow about 100 people with moderate to severe hemophilia A who are already taking efanesoctocog alfa (a clotting factor) as part of their routine care. Researchers will track joint health, bleeding rates, and safety over up to 5 years using medical records and imaging. The goal is to see how well the medicine works in everyday life to protect joints and reduce bleeds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

efanesoctocog alfa (a clotting factor medicine)

What this could lead to

If successful, this study could show that efanesoctocog alfa helps protect joints and reduce bleeding in people with hemophilia A in real-world use.

What could go wrong

This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also small (100 participants) and limited to Taiwan, so findings may not apply broadly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coagulation protein disease hemarthrosis hematologic disorder hemophilia A hemorrhagic disease hereditary disease inherited blood coagulation disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site Number : 1580001

    RECRUITING

    Taipei, 100, Taiwan

  • Investigational Site Number : 1580002

    RECRUITING

    Taipei, 114, Taiwan

  • Investigational Site Number : 1580003

    RECRUITING

    Taipei, 110, Taiwan

  • Investigational Site Number : 1580004

    RECRUITING

    Taoyuan City, 33305, Taiwan

  • Investigational Site Number : 1580005

    RECRUITING

    Taichung, 40201, Taiwan

  • Investigational Site Number : 1580006

    RECRUITING

    Taichung, 40447, Taiwan

  • Investigational Site Number : 1580007

    RECRUITING

    Taichung, 40705, Taiwan

  • Investigational Site Number : 1580008

    RECRUITING

    Changhua, 500, Taiwan

  • Investigational Site Number : 1580009

    RECRUITING

    Kaohsiung City, 807, Taiwan

  • Investigational Site Number : 1580010

    RECRUITING

    Kaohsiung City, 83301, Taiwan